Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers

Carla Verri, Cristina Borzi, Todd Holscher, Matteo Dugo, Andrea Devecchi, Katherine Drake, Stefano Sestini, Paola Suatoni, Elisa Romeo, Gabriella Sozzi, Ugo Pastorino, Mattia Boeri

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background The issue of overdiagnosis in low-dose computed tomography (LDCT) screening trials could be addressed by the development of complementary biomarkers able to improve detection of aggressive disease. The mutation profile of LDCT screening–detected lung tumors is currently unknown. Methods Targeted next-generation sequencing was performed on 94 LDCT screening–detected lung tumors. Associations with clinicopathologic features, survival, and the risk profile of a plasma microRNA signature classifier were analyzed. Results The mutational spectrum and frequency observed in screening series was similar to that reported in public data sets, although a larger number of tumors without mutations in driver genes was detected. The 5-year overall survival (OS) rates of patients with and without mutations in the tumors were 66% and 100%, respectively (p = 0.015). By combining the mutational status with the microRNA signature classifier risk profile, patients were stratified into three groups with 5-year OS rates ranging from 42% to 97% (p < 0.0001) and the prognostic value was significant after controlling for stage (p = 0.02). Conclusion Tumor mutational status along with a microRNA-based liquid biopsy can provide additional information in planning clinical follow-up in lung cancer LDCT screening programs.

Original languageEnglish
Pages (from-to)922-931
Number of pages10
JournalJournal of Thoracic Oncology
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Lung Neoplasms
Tomography
MicroRNAs
Survival
Neoplasms
Mutation
Survival Rate
Lung
Biomarkers
Biopsy
Genes

Keywords

  • Low-dose computed tomography
  • Lung cancer
  • MicroRNA-based liquid biopsy
  • Mutational load
  • Next-generation sequencing

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers. / Verri, Carla; Borzi, Cristina; Holscher, Todd; Dugo, Matteo; Devecchi, Andrea; Drake, Katherine; Sestini, Stefano; Suatoni, Paola; Romeo, Elisa; Sozzi, Gabriella; Pastorino, Ugo; Boeri, Mattia.

In: Journal of Thoracic Oncology, Vol. 12, No. 6, 01.06.2017, p. 922-931.

Research output: Contribution to journalArticle

Verri, Carla ; Borzi, Cristina ; Holscher, Todd ; Dugo, Matteo ; Devecchi, Andrea ; Drake, Katherine ; Sestini, Stefano ; Suatoni, Paola ; Romeo, Elisa ; Sozzi, Gabriella ; Pastorino, Ugo ; Boeri, Mattia. / Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers. In: Journal of Thoracic Oncology. 2017 ; Vol. 12, No. 6. pp. 922-931.
@article{9e150c0f2980467bb20c43b2fcda21f1,
title = "Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers",
abstract = "Background The issue of overdiagnosis in low-dose computed tomography (LDCT) screening trials could be addressed by the development of complementary biomarkers able to improve detection of aggressive disease. The mutation profile of LDCT screening–detected lung tumors is currently unknown. Methods Targeted next-generation sequencing was performed on 94 LDCT screening–detected lung tumors. Associations with clinicopathologic features, survival, and the risk profile of a plasma microRNA signature classifier were analyzed. Results The mutational spectrum and frequency observed in screening series was similar to that reported in public data sets, although a larger number of tumors without mutations in driver genes was detected. The 5-year overall survival (OS) rates of patients with and without mutations in the tumors were 66{\%} and 100{\%}, respectively (p = 0.015). By combining the mutational status with the microRNA signature classifier risk profile, patients were stratified into three groups with 5-year OS rates ranging from 42{\%} to 97{\%} (p < 0.0001) and the prognostic value was significant after controlling for stage (p = 0.02). Conclusion Tumor mutational status along with a microRNA-based liquid biopsy can provide additional information in planning clinical follow-up in lung cancer LDCT screening programs.",
keywords = "Low-dose computed tomography, Lung cancer, MicroRNA-based liquid biopsy, Mutational load, Next-generation sequencing",
author = "Carla Verri and Cristina Borzi and Todd Holscher and Matteo Dugo and Andrea Devecchi and Katherine Drake and Stefano Sestini and Paola Suatoni and Elisa Romeo and Gabriella Sozzi and Ugo Pastorino and Mattia Boeri",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.jtho.2017.03.001",
language = "English",
volume = "12",
pages = "922--931",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers

AU - Verri, Carla

AU - Borzi, Cristina

AU - Holscher, Todd

AU - Dugo, Matteo

AU - Devecchi, Andrea

AU - Drake, Katherine

AU - Sestini, Stefano

AU - Suatoni, Paola

AU - Romeo, Elisa

AU - Sozzi, Gabriella

AU - Pastorino, Ugo

AU - Boeri, Mattia

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background The issue of overdiagnosis in low-dose computed tomography (LDCT) screening trials could be addressed by the development of complementary biomarkers able to improve detection of aggressive disease. The mutation profile of LDCT screening–detected lung tumors is currently unknown. Methods Targeted next-generation sequencing was performed on 94 LDCT screening–detected lung tumors. Associations with clinicopathologic features, survival, and the risk profile of a plasma microRNA signature classifier were analyzed. Results The mutational spectrum and frequency observed in screening series was similar to that reported in public data sets, although a larger number of tumors without mutations in driver genes was detected. The 5-year overall survival (OS) rates of patients with and without mutations in the tumors were 66% and 100%, respectively (p = 0.015). By combining the mutational status with the microRNA signature classifier risk profile, patients were stratified into three groups with 5-year OS rates ranging from 42% to 97% (p < 0.0001) and the prognostic value was significant after controlling for stage (p = 0.02). Conclusion Tumor mutational status along with a microRNA-based liquid biopsy can provide additional information in planning clinical follow-up in lung cancer LDCT screening programs.

AB - Background The issue of overdiagnosis in low-dose computed tomography (LDCT) screening trials could be addressed by the development of complementary biomarkers able to improve detection of aggressive disease. The mutation profile of LDCT screening–detected lung tumors is currently unknown. Methods Targeted next-generation sequencing was performed on 94 LDCT screening–detected lung tumors. Associations with clinicopathologic features, survival, and the risk profile of a plasma microRNA signature classifier were analyzed. Results The mutational spectrum and frequency observed in screening series was similar to that reported in public data sets, although a larger number of tumors without mutations in driver genes was detected. The 5-year overall survival (OS) rates of patients with and without mutations in the tumors were 66% and 100%, respectively (p = 0.015). By combining the mutational status with the microRNA signature classifier risk profile, patients were stratified into three groups with 5-year OS rates ranging from 42% to 97% (p < 0.0001) and the prognostic value was significant after controlling for stage (p = 0.02). Conclusion Tumor mutational status along with a microRNA-based liquid biopsy can provide additional information in planning clinical follow-up in lung cancer LDCT screening programs.

KW - Low-dose computed tomography

KW - Lung cancer

KW - MicroRNA-based liquid biopsy

KW - Mutational load

KW - Next-generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=85015997533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015997533&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2017.03.001

DO - 10.1016/j.jtho.2017.03.001

M3 - Article

AN - SCOPUS:85015997533

VL - 12

SP - 922

EP - 931

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -